

LYNPARZA[®] FILM-COATED TABLETS

Olaparib (100mg & 150mg)

What is in this leaflet

1. What Lynparza is used for
2. How Lynparza works
3. Before you use Lynparza
4. How to use Lynparza
5. While you are using it
6. Side effects
7. Storage & Disposal of Lynparza
8. Product Description
9. Manufacturer and Product Registration Holder
10. Date of RiMUP Revision
11. Serial number

What Lynparza is used for

Lynparza is used for the treatment of:

- **A type of ovarian cancer (BRCA-mutated) that has responded to the first treatment with standard platinum-based chemotherapy.**
 - A test is used to find out whether you have *BRCA*-mutated ovarian cancer.
- **Ovarian cancer that has come back (recurred).** It can be used after the cancer has responded to previous treatment with standard platinum-based chemotherapy.
- **Advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer with a certain type of abnormal *BRCA* gene or a positive laboratory tumour test for genomic instability called HRD.** Lynparza is used in combination with another anti-cancer medicine, bevacizumab, as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that Lynparza is right for you.
- **A certain type of breast cancer (*BRCA*-mutated, *HER2*-negative) which has spread beyond the original tumour.** You should have received chemotherapy medicines either before or after your cancer has spread.
 - A test is used to find out whether you have *BRCA*-mutated breast cancer.
- **A certain type of breast cancer (*BRCA*-mutated, *HER2*-negative) when the cancer has not spread to other parts of the body and treatment is going to be given after surgery (treatment after surgery is called adjuvant therapy).** You should have received chemotherapy medicines before or after surgery.
 - A test is used to determine whether you have *BRCA*-mutated breast cancer.
- **Metastatic pancreatic cancer with a certain type of abnormal inherited *BRCA* gene.** Lynparza is used as maintenance treatment after your cancer has not progressed on at least 16 weeks of treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that Lynparza is right for you.
- **Prostate cancer with certain inherited or acquired abnormal genes called *BRCA* or *ATM* gene.** Lynparza is used when the cancer has spread to other parts of the body (metastatic), and no longer responds to a medical or surgical treatment that lowers testosterone, and has progressed after treatment with a new hormonal agent (such as enzalutamide or abiraterone). Your healthcare

provider will perform a test to make sure Lynparza is right for you.

- **Prostate cancer with a certain type of abnormal inherited or acquired *BRCA* gene that has spread to other parts of the body (metastatic) and no longer responds to a medical or surgical treatment that lowers testosterone.** Lynparza is used in combination with another anti-cancer medicine, abiraterone, together with the steroid medicine, prednisone or prednisolone.
- **A type of uterine cancer (MMR-proficient endometrial cancer) that has spread beyond the original tumour or come back (recurred).** Lynparza is used together with durvalumab if the cancer has not progressed after initial treatment with chemotherapy (carboplatin and paclitaxel) in combination with durvalumab.
 - A test is used to find out whether you have MMR-proficient endometrial cancer.

How Lynparza works

Lynparza contains the active substance olaparib. Olaparib is a type of cancer medicine called a PARP inhibitor (poly [adenosine diphosphate-ribose] polymerase inhibitor).

PARP inhibitors can destroy cancer cells that are not good at repairing DNA damage. These specific cancer cells can be identified by:

- Response to platinum chemotherapy, or
- Looking for faulty DNA repair genes, such as *BRCA* (BReast CAncer) genes.

When Lynparza is used in combination with abiraterone (an androgen receptor signalling inhibitor), the combination may help enhance anti-cancer effect in prostate cancer cells with or without faulty DNA repair genes (e.g., *BRCA* genes).

Before you use Lynparza

When you must not use it

Do not take Lynparza:

- If you are allergic to olaparib or any of the other ingredients of this medicine (see “*Ingredients*” section for more information).
- If you are breast-feeding (see “*While you are using it*” section for more information).

Do not take Lynparza if any of the above apply to you. If you are not sure, talk to your doctor, pharmacist, or nurse before taking Lynparza.

Before you start to use it

Talk to your doctor, pharmacist, or nurse before or during treatment with Lynparza:

- If you have low blood cell counts on testing. These may be low counts for red or white blood cells, or low platelet counts. See “*Side effects*” section for more information about these side effects, including the signs and symptoms you need to look out for (for example, fever or infection, bruising or bleeding). In a small number of patients, these may be a sign of more serious problems with the bone marrow such as ‘myelodysplastic syndrome’ (MDS) or ‘acute myeloid leukaemia’ (AML). When Lynparza is used in combination with another anti-cancer medicine (durvalumab), a low blood cell count could be a sign of ‘pure red cell aplasia’

(PRCA), a condition in which no red blood cells are produced, or ‘auto-immune haemolytic anaemia’ (AIHA), an excessive breakdown of red blood cells.

- If you experience any new or worsening symptoms of shortness of breath, coughing, or wheezing. A small number of patients treated with Lynparza reported inflammation of the lungs (pneumonitis). Pneumonitis is a serious condition that can often require hospital treatment.
- If you experience any new or worsening symptoms of pain or swelling in an extremity, shortness of breath, chest pain, breathing that is more rapid than normal or heart beats faster than normal. A small number of patients treated with Lynparza were reported to develop a blood clot in a deep vein, usually in the leg (venous thrombosis), or a clot in the lungs (pulmonary embolism).
- If you notice yellowing of your skin or the whites of your eyes, abnormally dark urine (brown coloured), pain on the right side of your stomach area (abdomen), tiredness, feeling less hungry than usual or unexplained nausea and vomiting, contact your doctor immediately as this may indicate problems with your liver.

If you think any of these may apply to you, talk to your doctor, pharmacist or nurse before or during treatment with Lynparza.

Tests and checks

Your doctor will check your blood before and during treatment with Lynparza.

You will have a blood test:

- before treatment.
- every month for the first year of treatment.

- at regular intervals decided by your doctor after the first year of treatment.

If your blood count falls to a low level, you may need to have a blood transfusion (where you are given new blood or blood-based products from a donor).

Taking other medicines

Tell your doctor, pharmacist, or nurse if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription and herbal medicines. This is because Lynparza can affect the way some other medicines work. Also, some other medicines can affect the way Lynparza works.

Tell your doctor, pharmacist, or nurse if you are taking or are planning to take any of the following medicines:

- Any other anti-cancer medicines.
- A vaccine or a medicine that suppresses the immune system, as you may need to be closely monitored.
- Itraconazole, fluconazole – used for fungal infections.
- Telithromycin, clarithromycin, erythromycin used for bacterial infections.
- Protease inhibitors boosted with ritonavir or cobicistat, boceprevir, telaprevir, nevirapine, efavirenz – used for viral infections, including HIV.
- Rifampicin, rifapentine, rifabutin – used for bacterial infections, including tuberculosis (TB).
- Phenytoin, carbamazepine, phenobarbital – used as a sedative or to treat fits (seizures) and epilepsy.
- Herbal remedies containing St John’s Wort (*Hypericum perforatum*) – used mainly for depression.
- Digoxin, diltiazem, furosemide, verapamil,

valsartan – used to treat heart conditions or high blood pressure.

- Bosentan – used to treat pulmonary artery hypertension.
- Statins, for example simvastatin, pravastatin, rosuvastatin – used to lower blood cholesterol levels.
- Dabigatran – used to thin the blood.
- Glibenclamide, metformin, repaglinide – used to treat diabetes.
- Ergot alkaloids – used to treat migraines and headaches.
- Fentanyl – used to treat cancer pain.
- Pimozide, quetiapine – used to treat mental health problems.
- Cisapride – used to treat stomach problems.
- Colchicine – used to treat gout.
- Cyclosporine, sirolimus, tacrolimus – used to suppress the immune system.
- Methotrexate – used to treat cancer, rheumatoid arthritis, and psoriasis.

Tell your doctor, pharmacist, or nurse if you are taking any of the above or any other medicines. The medicines listed here may not be the only ones that could affect Lynparza.

How to use Lynparza

Your doctor has prescribed Lynparza film-coated tablets for you.

How much to use

- Your doctor will tell you how many tablets of Lynparza to take. It is important that you take the total recommended dose each day. Keep doing so for as long as your doctor, pharmacist or nurse tells you to.
- The usual recommended dose is 300 mg (2 x 150 mg

tablets) twice a day – a total of 4 tablets each day.

Your doctor may prescribe a different dose if:

- you have problems with your kidneys. You will be asked to take 200 mg (2 x 100 mg tablets) twice a day – a total of 4 tablets each day.
- you are taking certain medicines that may affect Lynparza (see “*Taking other medicines*” section).
- you have certain side effects while you are taking Lynparza (see “*Side effects*” section). Your doctor may lower your dose or stop treatment, either for a short time or permanently.

When to use it

- Take Lynparza once in the morning and once in the evening.
- Swallow Lynparza tablets whole, with or without food.

How long to use it

Always take this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist, or nurse if you are not sure.

If you forget to use it

If you forget to take Lynparza, take your next normal dose at its scheduled time. Do not take a double dose (two doses at the same time) to make up for a forgotten dose.

If you use too much (overdose)

If you take more Lynparza than your normal dose, contact your doctor or the nearest hospital straight away.

While you are using Lynparza

Things you must do

Contraception, pregnancy, and breast feeding.

Female patients:

- You should not take Lynparza if you are pregnant or might become pregnant.

This is because it may harm an unborn baby.

- You should not become pregnant while taking this medicine. If you are having sex, you should use two effective methods of contraception while taking this medicine and for 6 months after taking the last dose of Lynparza. It is not known whether Lynparza may affect the effectiveness of some hormonal contraceptives. Please tell your doctor if you are taking a hormonal contraceptive, as your doctor may recommend the addition of a non-hormonal contraceptive method.
- You should have a pregnancy test before starting Lynparza, at regular times during treatment and 6 months after taking the last dose of Lynparza. If you become pregnant during this time, you must talk to your doctor straight away.
- It is not known whether Lynparza passes into breast milk. Do not breast-feed if you are taking Lynparza and for 1 month after taking the last dose of Lynparza. If you are planning to breast-feed, tell your doctor.

Male patients:

- You must use a condom when having sex with a female partner, even if she is pregnant, while taking Lynparza and for 3 months after taking the last dose. It is not known whether Lynparza passes into semen.
- Your female partner must also use a suitable method of contraception.
- You must not donate sperm while taking Lynparza and for 3 months after taking the last dose.

Things you must not do

- Do not chew, crush, dissolve or divide the tablets as this

may affect how quickly the medicine gets into your body.

- Do not drink grapefruit juice while you are being treated with Lynparza. It can affect the way medicine works.

Things to be careful of

Driving and using machines

Lynparza may influence your ability to drive and use machines. If you feel dizzy, weak, or tired while taking Lynparza, do not drive or use tools or machines.

Side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Tell your doctor straight away if you notice any of the following:

Side effects reported in clinical studies with patients receiving Lynparza alone:

Very common (may affect more than 1 in 10 people):

- feeling short of breath, feeling very tired, pale skin, or fast heart beat – these may be symptoms of a decrease in the number of red blood cells (anaemia).

Uncommon (may affect up to 1 in 100 people):

- allergic reactions (e.g., hives, difficulty breathing or swallowing, dizziness which are signs and symptoms of hypersensitivity reactions).
- itchy rash or swollen, reddened skin (dermatitis).
- serious problems with bone marrow (myelodysplastic syndrome or acute myeloid leukaemia). (See “Before you start to use it” section for more information). (may affect more than 1 in 100 people over their lifetime).
- inflammation of the lungs, which can cause coughing with a fever and difficulty breathing (pneumonitis).

Other side effects include:

Very common (may affect more than 1 in 10 people):

- feeling sick (nausea).
- being sick (vomiting).
- feeling tired or weak (fatigue).
- indigestion or heartburn (dyspepsia).
- loss of appetite.
- headache.
- changes in taste of foods (dysgeusia).
- feeling dizzy.
- cough.
- shortness of breath (dyspnoea).
- diarrhoea - if it gets severe, tell your doctor straight away.

Very common side effects that may show up in blood tests:

- low white blood cell count (leukopenia or neutropenia) which may decrease your ability to fight infection and may be associated with fever.

Common (may affect up to 1 in 10 people):

- rash.
- sore mouth (stomatitis).
- pain in the stomach area under the ribs (upper abdominal pain).
- blood clot in a deep vein, usually in the leg (venous thrombosis) that may cause symptoms such as pain or swelling of the legs, or a clot in the lungs (pulmonary embolism) that may cause symptoms such as shortness of breath, chest pain, breathing that is more rapid than normal or heart beats faster than normal.

Common side effects that may show up in blood tests:

- low white blood cell count (lymphopenia) which may decrease your ability to fight infection and may be associated with fever.

- decrease in the number of platelets in blood (thrombocytopenia) you may notice the following symptoms:
 - bruising or bleeding for longer than usual if you hurt yourself.
- increase in blood creatinine - this test is used to check how your kidneys are working.
- abnormal liver function tests.

Uncommon side effects that may show up in blood tests:

- increase in the size of red blood cells (not associated with any symptoms).

Rare (may affect up to 1 in 1,000 people):

- Face swelling (angioedema).
- Painful inflammation of the fatty tissue under the skin (erythema nodosum).

Not known (cannot be estimated from available data):

- signs of liver problems, such as yellowing of your skin or the whites of your eyes (jaundice), nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine (brown coloured), feeling less hungry than usual, tiredness.

Side effects reported in a clinical study with patients receiving Lynparza with durvalumab after initial treatment with chemotherapy (carboplatin and paclitaxel) with durvalumab, that occurred at a higher frequency than in patients receiving Lynparza alone:

Very common (may affect more than 1 in 10 people):

- decrease in the number of platelets in blood (thrombocytopenia), you may notice the following symptoms:
 - bruising or bleeding for longer than usual if you hurt yourself.
- rash.

Common (may affect up to 1 in 10 patients) side effects when using Lynparza with durvalumab:

- allergic reactions (e.g. hives, difficulty breathing or swallowing, dizziness which are signs and symptoms of hypersensitivity reactions).

In addition, the following side effect was reported in patients receiving Lynparza with durvalumab:

Common (may affect up to 1 in 10 patients):

- failure to produce red blood cells (pure red cell aplasia) which can be associated with symptoms of shortness of breath, fatigue, pale skin or fast heart beat.

Your doctor will test your blood every month for the first year of treatment and at regular intervals after that. Your doctor will tell you if there are any changes in your blood test that might need treatment.

Visit your doctor or pharmacist immediately if you experience any side effects after using this medicine.

You may report any side effects or adverse reactions directly to the National Centre for Adverse Drug Reaction Monitoring by visiting the website npra.gov.my [Consumers → Reporting Side Effects to Medicines (ConSERF) or Vaccines (AEFI)]

Storage and Disposal of Lynparza

Storage

Store below 30°C.

Keep this medicine out of the sight and reach of children.

Store in the original package in order to protect from moisture.

Disposal

Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

Product Description

What it looks like

Lynparza 100 mg tablets are yellow to dark yellow, oval, bi-convex, film-coated tablets, marked with “OP100” on one side and plain on the other.

Lynparza 150 mg tablets are green to green/grey, oval, bi-convex, film-coated tablets, marked with “OP150” on one side and plain on the other.

Lynparza is supplied in packs containing 56 film-coated tablets (7 blisters of 8 tablets each), or multipacks containing 112 (2 packs of 56) film-coated tablets.

Not all pack sizes may be marketed.

Ingredients

The active substance is olaparib.

- Each Lynparza 100 mg film-coated tablet contains 100 mg olaparib.
- Each Lynparza 150 mg film-coated tablet contains 150 mg olaparib.

The other ingredients (excipients) are:

- Tablet core: copovidone, silica colloidal anhydrous, mannitol, sodium stearyl fumarate.
- Tablet coating: hypromellose, macrogol 400, titanium dioxide (E171), iron oxide yellow (E172), iron oxide black (E172) (150 mg tablets only).

- This medicine contains less than 1 mmol sodium (23 mg) per 100 mg or 150 mg tablet, that is to say essentially “sodium-free”.

MAL number:

100mg: MAL19106011ACRZ

150mg: MAL19106013ACRZ

Manufacturer

AbbVie Limited
KM58.0 Carretera 2 Cruce Davila, Barceloneta, Puerto Rico (PR) 00617, United States.

Product Registration Holder

AstraZeneca Sdn. Bhd.
Level 11 & 12, The Bousteador, No. 10, Jalan PJU 7/6, Mutiara Damansara, 47800 Petaling Jaya, Malaysia.

Date of revision

14/10/2025

VV-RIM-01427519

[Based on PI VV-RIM-01427513]

Serial Number:

NPRA (R1/5) 16052024/096

NPRA (R1/A16) 100723/014